Table 1.
Comparison between T2DM versus non-T2DM in all patients.
| Variables | Total (n=182) | T2DM (n=91) | Non-T2DM (n=91) | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. Pts avail-able | Mean±SD or frequency (percentage) | Median (Range) | No. Pts avail-able | Mean±SD or frequency (percentage) | Median (Range) | No. Pts avail-able | Mean±SD or frequency (percentage) | Median (Range) | ||
| Sex (male/female), n (%) | 182 | 144 (79.1%)/38 (20.9%) | 91 | 72 (79.1%)/19 (20.9%) | 91 | 72 (79.1%)/19 (20.9%) | 1 | |||
| Age (years) | 182 | 56.18±7.72 | 56.21 (39.46–79.61) | 91 | 55.66±7.81 | 55.17 (39.46–78.5) | 91 | 56.69±7.63 | 56.76 (40.08–79.61) | 0.369 |
| Ascites, n (%) | 182 | 91 | 91 | 0.396 | ||||||
| No | 98 (53.8%) | 52 (57.1%) | 46 (50.5%) | |||||||
| Mild | 17 (9.3%) | 6 (6.6%) | 11 (12.1%) | |||||||
| Moderate to severe | 67 (36.8%) | 33 (36.3%) | 34 (37.4%) | |||||||
| HE, n (%) | 182 | 91 | 91 | 0.801 | ||||||
| No | 170 (93.4%) | 85 (93.4%) | 85 (93.4%) | |||||||
| Grade I–II | 9 (4.9%) | 5 (5.5%) | 4 (4.4%) | |||||||
| Grade III–IV | 3 (1.6%) | 1 (1.1%) | 2 (2.2%) | |||||||
| Laboratory tests | ||||||||||
| RBC (1012/L) | 182 | 3.32±0.84 | 3.32 (1.55–5.65) | 91 | 3.32±0.79 | 3.33 (1.76–4.99) | 91 | 3.32±0.87 | 3.22 (1.55–5.65) | 0.913 |
| Hb (g/L) | 182 | 102.54±31.18 | 102.5 (3.2–177) | 91 | 104.77±30.88 | 108 (48–177) | 91 | 100.30±3.48 | 98 (3.2–165) | 0.336 |
| WBC (109/L) | 182 | 5.82±5.15 | 4.4 (0.9–38) | 91 | 6.49±5.93 | 4.4 (1.3–38) | 91 | 5.14±4.16 | 4.3 (0.9–30.7) | 0.076 |
| PLT (109/L) | 182 | 98.68±63.45 | 82.5 (18–392) | 91 | 101.09±64.11 | 82 (23–316) | 91 | 96.27±63.05 | 83 (18–392) | 0.61 |
| TBIL (umol/L) | 182 | 42.8±93.66 | 20.5 (3.9–809.8) | 91 | 48.10±120.26 | 18.3 (3.9–809.8) | 91 | 37.50±55.89 | 23.5 (4.7–374.9) | 0.447 |
| ALB (g/L) | 182 | 32.81±6.40 | 33 (17.3–53.9) | 91 | 32.97±6.67 | 32.9 (18.9–47.5) | 91 | 32.64±6.14 | 33.2 (17.3–53.9) | 0.725 |
| ALT (U/L) | 182 | 55.10±127.62 | 30.5 (8–1460) | 91 | 56.25±152.28 | 29 (8–1460) | 91 | 53.95±97.79 | 31 (9–827) | 0.903 |
| AST (U/L) | 182 | 76.69±143.89 | 38.5 (11–1318) | 91 | 65.43±100.43 | 35 (12–819) | 91 | 87.96±176.91 | 40 (11–1318) | 0.292 |
| ALP (U/L) | 182 | 101.76±54.46 | 87 (39.3–392) | 91 | 103.85±54.34 | 88 (41–322.2) | 91 | 99.66±54.81 | 86 (39.3–392) | 0.605 |
| GGT (U/L) | 181 | 105.56±132.26 | 62 (8–994) | 91 | 110.15±131.24 | 61 (15–713) | 90 | 100.91±133.85 | 63 (8–994) | 0.64 |
| BUN (mmol/L) | 182 | 8.05±6.66 | 6.25 (1.54–55.01) | 91 | 8.96±6.51 | 6.54 (2.03–45.52) | 91 | 7.14±6.71 | 5.77 (1.54–55.01) | 0.066 |
| Cr (umol/L) | 182 | 82.89±94.87 | 59 (28–675) | 91 | 91.75±104.42 | 60 (35–668) | 91 | 74.04±80.03 | 56.5 (28–675) | 0.209 |
| K (mmol/L) | 182 | 4.07±0.46 | 4.0 (2.9–5.8) | 91 | 4.10±0.45 | 4.1 (3.1–5.11) | 91 | 4.04±0.48 | 4 (2.9–5.8) | 0.332 |
| Na (mmol/L) | 182 | 137.99±4.6 | 138.5 (109.2–150) | 91 | 137.85±4.45 | 138.3 (123.6–150) | 91 | 138.13±4.76 | 138.7 (109.2–148.5) | 0.676 |
| Ca (mmol/L) | 71 | 2.1±0.23 | 2.1 (1.35–2.82) | 37 | 2.12±0.23 | 2.14 (1.65–2.82) | 34 | 2.08±0.23 | 2.14 (1.35–2.76) | 0.483 |
| PT (second) | 182 | 16.09±3.77 | 15.2 (11–40.9) | 91 | 16.03±3.69 | 15.1 (11.5–35.6) | 91 | 16.14±3.86 | 15.2 (11–40.9) | 0.848 |
| APTT (second) | 182 | 41.99±8.24 | 40.45 (28.2–87.3) | 91 | 41.14±8.22 | 40 (29.1–87.3) | 91 | 42.84±8.22 | 41.5 (28.2–74.6) | 0.165 |
| INR | 182 | 1.31±0.43 | 1.2 (0.81–4.19) | 91 | 1.30±0.43 | 1.17 (0.83–3.7) | 91 | 1.32±0.43 | 1.21 (0.81–4.19) | 0.842 |
| Titer of HBV-DNA (104 copies/ml) | 58 | 729.50±3282.64 | 11 (0.11–24000) | 25 | 302.61±984.20 | 4 (0.12–4200) | 33 | 1052.91±4268.20 | 29 (0.11–24000) | 0.393 |
| Child-Pugh class, n (%) | 182 | 91 | 91 | 1 | ||||||
| A | 80 (44%) | 40 (44%) | 40 (44%) | |||||||
| B | 82 (45.1%) | 41 (45.1%) | 41 (45.1%) | |||||||
| C | 20 (11%) | 10 (11%) | 10 (11%) | |||||||
| Child-Pugh score | 182 | 7.24±1.97 | 7 (5–14) | 91 | 7.24±1.97 | 7 (5–14) | 91 | 7.24±1.97 | 7 (5–14) | 1 |
| MELD score | 182 | 6.74±7.22 | 4.45 (−4.19–43.1) | 91 | 7.21±7.83 | 5.02 (−4.19–43.1) | 91 | 6.26±6.56 | 4.35 (−3.39–37.57) | 0.377 |
| FPG (mmol/L) | 88 | 9.17±4.50 | 8.44 (3.92–34.47) | 88 | 9.17±4.50 | 8.44 (3.92–34.47) | 0 | NA | NA | NA |
| HA1C (%) | 17 | 8.3±3.07 | 7.3 (4.8–15.6) | 17 | 8.3±3.07 | 7.3 (4.8–15.6) | 0 | NA | NA | NA |
| Duration (years) | 76 | 6.79±5.66 | 6 (0.00–28) | 76 | 6.79±5.66 | 6 (0.00–28) | 0 | NA | NA | NA |
| HCC, n (%) | 182 | 73 (40.1%) | 91 | 31 (34.1%) | 91 | 42 (46.2%) | 0.13 | |||
| Number of HCC lesions | 58 | 24 | 34 | 0.596 | ||||||
| 1 | 32 (55.2%) | 14 (58.3%) | 18 (52.9%) | |||||||
| 2–3 | 5 (8.6%) | 1 (4.2%) | 4 (11.8%) | |||||||
| >3 | 21 (36.2%) | 9 (37.5%) | 12 (35.3%) | |||||||
| Maximum diameter of HCC lesion (cm) | 48 | 5.67±3.60 | 4.75 (1.40–15.5) | 21 | 5.59±3.60 | 5.2 (1.5–12.2) | 27 | 5.74±3.67 | 4.6 (1.4–15.5) | 0.882 |
ALB – albumin; ALP – alkaline phosphatase; ALT – alanine aminotransferase; APTT – activated partial thromboplastin time; AST – aspartate aminotransferase; BUN – blood urea nitrogen; Ca – calcium ion; Cr – creatinine; Duration – the duration of T2DM; FPG – fasting plasma glucose; GGT – γ-glutamine transferase; HE – hepatic encephalopathy; HCC – hepatocellular carcinoma; HA1C – glycosylated hemoglobin; Hb – hemoglobin; INR – international normalized ratio; K – potassium ion; MELD – model for end-stage liver disease; Na – sodium ion; NA – not available; PLT – platelet; PT – prothrombin time; Pts – patients; RBC – red blood cell; T2DM – type 2 diabetes; TBIL – total bilirubin; WBC – white blood cell.